Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Efficacy and Safety of PAZ320 on PPG and Insulin Blood Levels in Type II Diabetic Patients (PAZ320)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04569214
Recruitment Status : Withdrawn
First Posted : September 29, 2020
Last Update Posted : September 29, 2020
Sponsor:
Information provided by (Responsible Party):
Boston Therapeutics

Brief Summary:
The purpose of this study is to test the efficacy of PAZ320 in diabetic patients.

Condition or disease Intervention/treatment Phase
Type II Diabetes Drug: PAZ320 Other: Placebo Phase 2

Detailed Description:
The purpose of the present clinical study is to test the efficacy of two doses of PAZ320 in diabetic patients already on treatment with metformin, in order to assess and quantify its effect on postprandial glucose and insulin levels after a standard meal composed of rice, compared to placebo.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Comparative, Dose-Escalating, Placebo-Controlled Study of the Efficacy and Safety of PAZ320, Ingested Together With a Standard Meal on Post-Prandial Glucose and Insulin Blood Levels in Type II Diabetic Patients Treated With Metformin
Actual Study Start Date : September 2012
Estimated Primary Completion Date : February 2013
Estimated Study Completion Date : February 2013

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Placebo Comparator: A - Placebo Control
4 tablets of placebo
Other: Placebo
Treatment arm A - 4 tablets of placebo Treatment arm B - 2 tablets of PAZ320 and 2 tablets of placebo, total of 4 tablets

Experimental: B - PAZ320 Low Dose
2 tablets of PAZ320 and 2 tablet of placebo
Drug: PAZ320
Treatment arm B - 2 tablets of PAZ320 and 2 tablets of placebo, total of 4 tablets Treatment arm C - 4 tablets of PAZ320
Other Name: Galactomannan

Other: Placebo
Treatment arm A - 4 tablets of placebo Treatment arm B - 2 tablets of PAZ320 and 2 tablets of placebo, total of 4 tablets

Experimental: C - PAZ320 High Dose
4 tablet of PAZ320
Drug: PAZ320
Treatment arm B - 2 tablets of PAZ320 and 2 tablets of placebo, total of 4 tablets Treatment arm C - 4 tablets of PAZ320
Other Name: Galactomannan




Primary Outcome Measures :
  1. Assess the PAZ320 effect on postprandial blood glucose levels in type II diabetic patients. [ Time Frame: 2 weeks ]
    The extent and duration of PAZ320 effect on postprandial blood glucose levels in type II diabetic patients will be assessed under treatment with metformin, over 4 hours after the intake of a standard meal, using an implanted continuous glucose monitoring device.


Secondary Outcome Measures :
  1. Number of Subjects with Adverse Events as a Measure of Safety and Tolerability [ Time Frame: 2 weeks ]
    The secondary safety endpoint is number subjects with occurrences of following AEs: injury, surgery, accidents, or illnesses, and significant abnormalities in clinical laboratory values, psychological testing, or physical examination findings. In cases of surgical or diagnostic procedures, the condition/illness leading to such a procedure will be considered as the AE rather than the procedure itself.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   35 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Patients diagnosed with type II diabetes since at least one year, not presenting any complications of their disease.
  2. Patients under treatment with Metformin up to 3g/day, given twice or three times daily. Metformin doses should not exceed 3g/day, and should be well tolerated by the patients, its dose should have been stable for the last 3 months before inclusion in the study. Metformin should be taken in the morning of the visit only after the test meal is taken. The next doses of metformin will be taken with meals after the visit, in the habitual order the patient is used to take. The patients should not stop taking metformin during the study, but continue as usual, except that in the mornings of the visits, as the patients arrive in fasting conditions, metformin should be taken after the test meal. If a concomitant combination with an oral anti diabetic agent is given, because of elevated HbA1c levels, it should be taken together with metformin after the test meal.
  3. Age - between 35 and 65, male and female.
  4. Females should not be pregnant or breast feeding, women of child bearing potential should guarantee anti-contraceptive measures.
  5. BMI (body mass index) - between 25 and 32.
  6. Patients with glycated hemoglobin (HbA1c) lower than 9%, and higher than 6.5%, HbA1c will be determined in the first visit.
  7. Patients who are able to collaborate during the entire duration of the study.

Exclusion Criteria:

  1. Patients with other underlying diseases, such as cardiovascular disease, renal disease, peripheral vascular disease or any condition considered to be a complication of diabetes, should be excluded from this study.
  2. Patients treated with insulin subcutaneous injections or with GLP-1 agonists, or by alpha-glucosidase inhibitors or by glinides should not be included in the study.
  3. HbA1c higher than 9%, or lower than 6.5%
  4. Women who are either pregnant or lactating
  5. Participation in another clinical study in the month preceding recruitment into the study.
  6. Patients who cannot guarantee compliance.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04569214


Locations
Layout table for location information
France
Department of Internal Medicine, Infectious Diseases and Diabetology Hopital Robert Bisson (Lisieux)
Lisieux, Normandy, France, 14107
Sponsors and Collaborators
Boston Therapeutics
Investigators
Layout table for investigator information
Principal Investigator: LOÏK GEFFRAY, MD Department Of Internal Medicine, Infectious Diseases And Diabetology Hopital Robert Bisson (Lisieux) Lisieux, Normandy, France
Layout table for additonal information
Responsible Party: Boston Therapeutics
ClinicalTrials.gov Identifier: NCT04569214    
Other Study ID Numbers: PAZ320-003
First Posted: September 29, 2020    Key Record Dates
Last Update Posted: September 29, 2020
Last Verified: September 2020
Keywords provided by Boston Therapeutics:
PAZ320
Type II diabetes
Metformin
Galactomannan
Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetes Mellitus, Type 2
Diabetes Mellitus
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases